Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Scholar Rock Holding Corporation enters the final stretch before its November 11 earnings with a deteriorating price trend, a short position that has grown steadily for six weeks, and a Street that remains broadly bullish but is watching for signs that the ISEMBYLD commercial launch is gaining traction.
The stock has lost 23% over the past month, closing at $42.20, and shed another 12.7% this week alone. That puts it well below the consensus analyst price target of around $70, implying meaningful upside on paper. The selloff has been broad across mid-cap biotech; peers INSM fell 10.9% on the week and RYTM dropped 7.1%, suggesting sector pressure rather than company-specific news is driving much of the move. was the notable outlier, gaining 17.7% on the week. SRRK is underperforming even in a weak tape.
Short positioning has climbed consistently since early September, and that trend is the most structurally interesting feature of this setup right now. Short interest has risen to just under 20% of free float, up from around 18.2% at the start of September, an increase of roughly 11.5% over 30 days. The pace of that build, steady and sustained rather than a single spike, suggests an organised thesis rather than opportunistic momentum shorts. The ORTEX short score has held in the mid-74s all week, ranking in the 8th percentile for short positioning within its sector. Despite the elevated short interest, however, the borrow market itself is not signalling stress. Availability is comfortable at 242%, meaning there are roughly 2.4 shares available to lend for every share already borrowed. Cost to borrow has edged higher, up 20% over the week and 25% over the month, but at 0.56% it remains low by any standard. Shorts are not paying a premium to maintain their positions.
Options traders have moved modestly more defensive as the stock has sold off. The put/call ratio is running at 0.80, slightly above its 20-day average of 0.74, though still only 0.4 standard deviations above the mean. The 52-week range on the PCR goes from 0.15 to 1.76, so the current reading sits well within normal bounds. This is a stock where options positioning is cautious but not alarmed.
The Street remains heavily skewed to the bull side, and the September analyst activity told a clear story. A wave of target price increases followed what appeared to be a catalyst event around September 14-15: Raymond James lifted to $72, BMO Capital raised to $84, Evercore ISI moved to $72, Piper Sandler jumped from $60 to $75, and Jefferies raised to $65. JP Morgan followed on September 21, lifting its Overweight target from $63 to $70. Truist added a further nudge to $77 on September 24. The one dissent came from Barclays, which downgraded to Equal-Weight while lifting its target from $55 to $58, a move that flagged valuation or risk concerns even as it acknowledged improving fundamentals. The mean target of around $70 implies roughly 66% upside from current levels, a gap that reflects either genuine dislocation or genuine uncertainty about the commercial ramp.
The bull case centres on ISEMBYLD's FDA-approved broad SMA label, first-in-class status, and net pricing expectations around $310,000 per patient per year. With roughly 6,600 US patients already on SMN2-targeting therapy eligible for add-on treatment, bulls see a path to $2.2 billion in 2035 revenue. Bears point to payer-duration risk, the possibility that insurers treat ISEMBYLD differently from established SMA modifiers, and the capital-intensive nature of an early-stage commercial launch with no durable earnings base yet. The price-to-book multiple has compressed sharply over the past month, falling by roughly 6.8 points, consistent with a market that is discounting the commercial story more heavily than analysts are.
One item on the register worth flagging: Srinivas Akkaraju holds a Schedule 13D position at 7.2% of the class, filed in October 2025. A 13D signals activist or at minimum engaged intent, and that stake has been on the books for a year now. Separately, Invus Public Equities trimmed from 11.4% to 8.0% as of its August 2026 filing, and Redmile Group cut from 7.6% to 3.6% across its filings, a meaningful reduction from a specialist healthcare fund that previously held a substantial position. FMR remains the largest reported institutional holder at nearly 15%, and BlackRock added roughly 2 million shares in the September quarter. The net institutional picture is mixed: some long-term holders are trimming, while index and large-cap managers have been adding.
Wikipedia traffic for the company spiked to a z-score of 4.3 relative to its own 90-day history as of late September, a notable retail attention signal that coincided with the FDA approval news cycle. That kind of attention spike can cut both ways in a stock with 20% short interest and a compressed price.
With earnings on November 11, the next 34 days will likely centre on any early commercial data for ISEMBYLD, prescription trends across the roughly 140 treatment centres and 2,600 physicians cited in the launch profile, and whether the bear thesis around payer behaviour starts to show up in net realised pricing versus the $310,000 per patient assumption the bulls are modelling.
See the live data behind this article on ORTEX.
Open SRRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
